Qu Biologics qubiologics.com


Public list: BIO 2016 (619) Pharma Startups (4743) Cancer Therapeutics (1148)

Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to restore the body's normal immune response. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and immune-related disease. The company has initiated clinical trials in Crohn's disease, ulcerative colitis and recurrent lung cancer.

Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to restore the body's normal immune response. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse...Show all

Company (Alive / Active)

Phone: 604-734-1450

Fax:

4475 Wayburne Drive
Suite 305
Burnaby, V5G 4X4
British Columbia, Canada

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Qu Biologics $5.9M Jun 5, 2018

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Qu Biologics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.